Articles related to TARGETED THERAPIES

Researchers have identified insufficient activation of the aryl hydrocarbon receptor (AHR) pathway as a key driver in lupus pathogenesis, offering a new target for therapeutic intervention.

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.